Analyst Price Targets — CMPX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 1:13 pm | — | Craig-Hallum | $15.00 | $6.52 | TheFly | Compass Therapeutics initiated with a Buy at Craig-Hallum |
| February 4, 2026 11:36 am | — | Canaccord Genuity | $13.00 | $6.42 | TheFly | Compass Therapeutics price target raised to $13 from $10 at Canaccord |
| January 6, 2026 3:11 pm | Sean McCutcheon | Raymond James | $9.00 | $4.89 | StreetInsider | Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) |
| December 3, 2025 10:02 am | Reni Benjamin | JMP Securities | $10.00 | $5.22 | TheFly | Compass Therapeutics initiated with an Outperform at Citizens JMP |
| October 6, 2025 10:30 am | — | Compass Point | $10.00 | $3.70 | TheFly | Compass Therapeutics initiated with an Outperform at LifeSci Capital |
| April 2, 2025 10:17 am | Andrew Berens | Leerink Partners | $6.00 | $1.69 | TheFly | Compass Therapeutics upgraded to Outperform from Market Perform at Leerink |
| September 16, 2024 6:49 am | Aydin Huseynov | Compass Point | $5.00 | $1.65 | StreetInsider | Ladenburg Thalmann Upgrades Compass Therapeutics (CMPX) to Buy |
Latest News for CMPX
Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the quarter Transaction represented a 1.89% change relative to the fund's reported 13F AUM Post-trade holding: 2,532,419 shares valued at $13.60 million as of December 31, 2025 The new CMPX stake represented 1.89% of AUM,…
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk.
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CMPX.
U.S. House Trading
No House trades found for CMPX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.